George Golumbes­ki signs on at a Eu­ro­pean spe­cial­ist VC firm with $265M to bet on ge­net­ic dis­eases

Since de­camp­ing from Cel­gene dur­ing a man­age­ment over­haul close to three years ago, George Golumbes­ki has been chan­nel­ing years of con­nec­tions and deal­mak­ing ex­pe­ri­ence to a se­lect group of com­pa­ny boards as a self-styled in­de­pen­dent biotech ex­ec — while dab­bling in a some­what be­hind-the-scenes role in ven­ture cap­i­tal at places like ARCH and Ver­tex Ven­tures.

He’s now adding one more gig to that menu, this time to scout promis­ing start­up ideas for ge­net­ic dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER